Back to Search
MARK SOCINSKI, MD
MD
Hematology & Oncology Physician
NPI: 1740341726IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
009500454(NC)ME128890(FL)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
UNIVERSITY OF VERMONT COLLEGE OF MEDICINE
Class of 1984
Research & Publications (20)
Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy.
PMID 19179904·J Thorac Oncol·2009
6-review
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
PMID 19487379·J Clin Oncol·2009
5-case
Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
PMID 19470913·J Clin Oncol·2009
8-other
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
PMID 19188136·Ann Oncol·2009
3-trial
Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer.
PMID 19561551·J Thorac Oncol·2009
5-case
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
PMID 19188545·Chest·2009
3-trial
Current treatments for advanced stage non-small cell lung cancer.
PMID 19349493·Proc Am Thorac Soc·2009
6-review
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
PMID 19096310·J Thorac Oncol·2009
3-trial
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
PMID 19632943·Clin Lung Cancer·2009
3-trial
Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer.
PMID 19437096·Ann Nucl Med·2009
5-case
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
PMID 19487960·J Thorac Oncol·2009
8-other
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).
PMID 18781341·Support Care Cancer·2009
8-other
Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
PMID 18978567·J Thorac Oncol·2008
3-trial
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
PMID 18978563·J Thorac Oncol·2008
3-trial
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
PMID 19027483·Lancet·2008
3-trial
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
PMID 18594318·J Thorac Oncol·2008
3-trial
Bevacizumab as first-line treatment for advanced non-small cell lung cancer.
PMID 18536787·Drugs Today (Barc)·2008
6-review
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
PMID 18520802·J Thorac Oncol·2008
3-trial
The current status and evolving role of sunitinib in non-small cell lung cancer.
PMID 18520293·J Thorac Oncol·2008
6-review
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
PMID 18784157·Oncologist·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2501 N ORANGE AVE STE 689
ORLANDO, FL 32804 - Phone
- (407) 303-2024
Quick Facts
- NPI
- 1740341726
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile